The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral Integrase (IN) enzyme catalyses integration. IN is an ideal therapeutic enzyme targeted by several drugs; raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG) and bictegravir (BIC) having been approved by the USA Food and Drug Administration (FDA). Due to high HIV-1 diversity, it is not well understood how specific naturally occurring polymorphisms (NOPs) in IN may affect the structure/function and binding affinity of Integrase Strand Transfer Inhibitors (INSTIs). In this study, we applied computational methods of molecular modelling and docking to analyse the effect of NOPs on the full-length IN structure and INSTI binding. We identified 16 NOPs within the Cameroonian derived CRF02_AG IN sequences and further identified 17 NOPs within HIV-1C South African sequences. The NOPs in the IN structures did not show any effect on INSTI binding. INSTIs displayed similar binding affinities to each IN structure. All INSTIs are clinically effective against diverse HIV-1 strains from INSTI treatment naïve populations. This study supports the use of second-generation INSTI DTG as part of first-line combination antiretroviral therapy (cART) regimens, due to DTG possessing a stronger genetic barrier to the emergence of drug resistance.
Introduction
The HIV/AIDS pandemic continues to be a significant problem worldwide [1] . The viral integration process, which is the insertion of viral DNA into host genomic DNA is an indispensable step of the retroviral life cycle and is catalyzed by the viral Integrase (IN) enzyme [2] . Integration is achieved via two distinct sequential catalytic activities, 3' processing and strand transfer. IN first processes viral DNA by excising a dinucleotide at the 3' end, exposing hydroxyl ends. IN then catalyses the introduction of the prepared DNA into genomic DNA by facilitating a nucleophilic attack upon genomic DNA [3, 4] . The same active site in IN, which contains a retroviral highly conserved DDE motif and magnesium ions, perform both activities [5, 6] . HIV-1 IN is a 32kDa protein that functions as a tetramer or multimer [3, 4] . A monomer consists of 3 distinct domains; the Nterminal domain (NTD) comprising residues 1-46, the catalytic core domain (CCD) comprising residues 56 -186 within which the active site DDE motif (Aspartate (D64), Aspartate (D116) and
Glutamate (E152) is present and the C-terminal domain (CTD) comprising residues 195 -288 [7, 8] . Several Integrase Strand Transfer Inhibitors (INSTIs) have been developed that targets HIV-1 IN to prevent viral integration into the host genome. The four INSTIs available thus far include; Raltegravir (RAL) and Elvitegravir (EVG) that are considered as first generation inhibitors, while Dolutegravir (DTG) and Bictegravir (BIC), along with the late-phase clinically trial Cabotegravir (CBT), are classified as second generation INSTIs [9] .
At present, first-line antiretroviral regimens for HIV-1 are expected to include the INSTI DTG according to World Health Organisation (WHO) recommendations [10] , because it has been shown to possess a higher genetic barrier to drug resistance development as compared with RAL and EVG [11] . HIV-1 is a genetically, highly diverse virus, forming different subtypes, recombinant and region specific variants [12] . Development of INSTIs, as with most pharmaceutical agents were primarily conducted by companies in first world nations, where subtype B is the most predominant variant [13, 14] . It remains unclear what effects naturally occurring polymorphisms (NOPs) may have upon the IN structure and INSTI susceptibility. This lack of data poses a challenge in drawing conclusions regarding the effects NOPs on the binding of INSTIs to HIV-1 IN subtypes [15] [16] [17] [18] [19] .
In this study computational methods, which include molecular modelling and docking, were used to determine if NOPs affect INSTI binding to HIV-1C IN subtype C and a circulating recombinant form of HIV-1 IN CRF_02_AG. The recently resolved Cryogenic-Electron Microscopy full-length HIV-1 subtype B IN structure, allowed us to build accurate and complete tetrameric threedimensional structures of HIV-1C IN and of HIV-1 IN CRF_02_AG. The value of having accurate Protein models allows us to infer the exact mode of interactions formed between active site residues of HIV-1 subtypes and drug atoms.
HIV-1 Subtype C derived from a South African cohort was chosen as one of our IN models, as it represents the most prevalent subtype both globally and for sub-Saharan Africa in particular [14, 19] . Our focus on a Cameroonian cohort was spurred on by the previously reported HIV-1 diversity present in Cameroon with all known subtypes/variants found within Cameroon [20, 21] . Furthermore, the full-length Cryo-EM HIV-1 IN structure, which was used as the template in our molecular modelling, served additionally as a subtype B IN model in our study, the predominant strain in developed nations.
Materials and Methods

Ethics Statement
The study used sequences from two African settings: South Africa and Cameroon. Ethical permission for this study was obtained from the Health Research Ethics Committee of Stellenbosch University (N14/10/130 and N15/08/071). The study was conducted according to the ethical guidelines and principles of the international Declaration of Helsinki 2013, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC), Ethical Guidelines for Research. A waiver of consent was awarded to conduct sequence analyses.
Study design
HIV-1-positive plasma samples were obtained from the Centre for the Study and Control of Communicable Diseases (CSCCD), University of Yaoundé I, Cameroon and In South Africa samples were requested, with permission, through the National Health Laboratory Services (NHLS) within the Division of Medical Virology, Stellenbosch University, and the South African National Health Laboratory Services (NHLS). Samples were collected between March 2017 and February 2018. We excluded patient samples with no previous cART history and patients receiving first-line cART treatment. Patients had their samples sent for HIV-1 genotypic resistance testing to the NHLS. Treatment failure is defined according to the South Africa adult antiretroviral guidelines by a confirmed viral load of >1000 copies/mL on two measurements taken two to three months apart.
Nucleic acid extraction
HIV-1 RNA extraction was performed using the QIAamp Viral RNA Mini Extraction Kit's Spin protocol, according to the manufacturer's instructions (Qiagen, Germany). Briefly, 140 µl of plasma was used as a starting volume. Larger starting volumes of 280 µl of plasma was used for samples with very low viral titres. Viral RNA was stored at -80ºc until use.
PCR amplification and sequencing
The synthesis of complementary DNA (cDNA) and first-round PCR amplification was performed using the Invitrogen SuperScript® III Reverse Transcriptase (RT) reagents (Invitrogen, Germany), as per the manufacturer's instructions. In-house amplification of the IN region (867 bp, positions 4230-5096, HXB2 strain) by nested RT-PCR was performed as previously described by our laboratory [22, 23] . Purified amplicons were sequenced on both strands with conventional Sanger DNA sequencing, using the ABI Prism Big Dye® Terminator sequencing kit version 3.1 and run on the ABI 3130xl automated DNA sequencer (Applied Biosystems, USA), according to manufactures instructions. Primers spanning the full-length integrase (867 bp) were used to sequence the PCR products in both directions. These include sequencing primers, Poli6 and Poli7 and additional sequencing primers were used namely; Poli2 (TAAARACARYAGTACWAATGGCA), relative to position 4745-4766 and KLVO83 (GAATACTGCCATTTGTACTGCTG), corresponding to position 4750-4772.
Consensus sequence alignment
We performed a search on the HIV Los Alamos National Library (LANL) database (https://www.hiv.lanl.gov/components/sequence/HIVsearch.com). Our search inclusion criteria included all Cameroonian HIV-1 subtype CRF02_AG IN sequences identified from treatment naïve patients. We selected one sequence per patient and all problematic sequences were excluded from further analyses. Finally, the consensus sequence representing CRF02_AG was generated using the CRF02_AG study sequences as previously reported [24] , database-derived HIV-1 CRF02_AG sequences (n = 100), while the consensus sequence for subtype C was derived from cohort sequences (n = 91, ) as reported in [23] . Nucleotide sequences were verified for stop codons, insertion and deletions using an online quality control program on the HIVLANL database (https://www.hiv.lanl.gov/content/sequence/QC/index.htm). Multiple sequence alignments were done with MAFFT version 7, from which the consensus sequence was derived [25] . As part of quality control, each of the viral sequences were inferred on a phylogenetic tree in order to eliminate possible contamination. The amino acid sequence alignment was extensively screened for the presence of primary and secondary resistance-associated mutations (RAMs) and NOPs associated with resistance to known INSTIs.
Protein modelling
A three dimensional model was constructed for HIV-1C IN and recombinant form CRF02_AG using Schrodinger Prime modelling software [26, 27] . A suitable homologous template was identified by performing a Blastp search using the consensus amino acid sequences of HIV1C IN and recombinant form CRF02_AG. Prior to modelling, missing residues were fixed by re-modelling the structure of template 5U1C using Schrodinger PRIME modelling software [28] . The Cryo-EM solved IN subtype B intasome structure (ID: 5U1C) was used as the homologous template for comparative modelling, as it shared a high sequence identity and coverage with HIV-1C IN from a South African cohort and with the recombinant form CRF02_AG from a Cameroonian cohort.
Protein preparation
Processing of protein models was performed using Schrodinger Protein Preparation Wizard, which added hydrogen atoms, created disulphide bonds, assigned bond orders, filled in any missing side-chains and optimized the H-Bonds [29] . Magnesium ions were extracted from the Prototype Foamy Virus (PFV) intasome structure by superimposition of the active site of HIV-1 integrase models with the PFV active site (ID:3lV), which was chosen due to high active site conservation between PFV integrase and HIV-1 integrase.
Model validation
To assess the quality of the constructed IN Protein models, a variety of structural parameters were tested within each model. The Structural Analysis and Verification Server (SAVES) was used for this purpose and includes the tools; Procheck, Whatcheck, Prove, Verify3D, ERRAT [30] [31] [32] [33] [34] . The cut-off values used by the tools were as follows >80% for Verify3D, <1% for Prove, >50 for ERRAT. Whatcheck and Procheck are further subdivided into tests, but both make use of a Ramachrandran plot analysis, which is deemed passed if the majority of residues are within the allowable region.
Furthermore, root mean square deviation (RMSD) analysis was conducted using PYMOL Maestro molecular visualising software to compare backbone structural similarity to the experimentally solved 5U1C template structure [35] .
Energy Minimisation
To reduce any steric clashing within the IN protein models, energy minimisation was performed using Gromacs version 2018.1. This included 5000 steps of energy minimisation using the steepest descent algorithm converging to a maximum force of <10.0 KJ/mol. The CHARMM 36 force field was used because it generates accurate topology parameters for proteins and has been previously applied to the study of IN [36 -38] .
Molecular docking and Interaction analysis
Molecular docking assays was performed using SMINA a fork of AUTODOCK VINA [39, 40] . The 3D Structures for the INSTI ligands were acquired from the ZINC database. Conversion of receptor and ligand structures from the respective pdb and sdf formats to pdbqt was done using OBABEL [41] . The docking grid was centred on the active site with a box size of 20Å in all planes. Each of the drugs were docked to each subtype structural intasome HIV-1C, B and AG, respectively. Ranking of generated binding poses was done based on the binding affinity values calculated using the Vinardo Scoring function [42] . Refinement of top ranked docking poses was done using the protein preparation wizard of Schrodinger Maestro software. The ligand interaction diagram 2D viewer within Schrodinger Maestro was used to calculate protein-ligand interactions.
Binding site analysis
The spatial and chemical features of the active sites containing the DDE motif of each IN subtype was compared to one another using PYMOL/MAESTRO. Briefly, the residues encompassing the binding site was determined by aligning each IN-INSTI complex to one another and extracting all residues within a 5Å radius of the inhibitor binding site. The binding sites, were superimposed to determine any difference in Root Mean Square Deviation (RMSD) for the backbone.
Results
Sequence alignments and protein structure prediction
Two IN consensus protein sequences, corresponding to the South African and Cameroonian cohorts respectively, were aligned to the sequence of the subtype B IN structure (ID:5u1c) ( Fig. 1) The sequence identity was calculated to 98% for both sequences when compared to subtype B. The alignment revealed 16 NOPs within the Cameroonian cohort derived CRF02_AG IN sequences. The identified polymorphisms being K14R, V31I, V72I, L101I, T112V, V113I, T124A, T125A, G134N, I135V, K136T, I151V, V201I, T206S, V234I, S283G. The alignment also showed 17 NOPs within a South African cohort derived Subtype C consensus sequence namely D25E, V31I, M50I, V72I, F100Y, L101I,  T112V, V113I, T124A, T125A, K136Q, I151V, V201I, T218I, V234I, R269K , D278A, S283G. The constructed IN models were validated with the following scores obtained with the SAVES server tests. CRF02_AG IN; Verify3D 71%, ERRAT 93/100, Prove 7.8% and for the Ramachandran plot analysis 86.1% of residues are within most favoured region. Subtype C IN; Verify3D 74%, ERRAT 92/100, Prove 7.8% and for the Ramachandran plot analysis 86.1% of residues are within most favoured region. Subtype B IN; Verify3D 71%, ERRAT 92/100, Prove 10.3% and for the Ramachandran plot analysis 82.6% of residues are within most favoured region.
RMSD analysis score was ~0.4Å in difference between all 3 structures. In addition, there was minimal difference in secondary structural makeup (Figure2). However, reference subtype B structure forms an extra helical turn absent in Subtype C and CRF02_AG. 
Molecular docking and Interaction analysis
The conducted molecular docking assays of the five FDA approved and/ late phase clinical trial INSTI's showed minimal differences, with less than 3kcal/mol difference observed in predicted binding affinities between each IN structure. (Table 1) . 
Binding site analysis
We calculated differences in total surface area, with 860Å 2 for subtype B IN, 969Å 2 for subtype C IN and 1041Å 2 for CRF_02_AG IN. RMSD analysis show that subtype C IN and CRF_02_AG deviate by 0.309Å and 0.44Å, respectively. The NOP I151V were found to occur within the binding site, but does not directly interact with INSTI's. NOP I151V is present in both subtype C and CRF_02_AG IN's. Both residue types have side-chains, which are highly unreactive and therefore play no functional role, however side-chain constituents and orientations may affect the spatial volume of the binding cavity.
Discussion
The NOPs that have been identified in subtype C and CRF_02_AG IN have not been previously associated with HIV-1 IN drug resistance, with the exception of the polymorphism M50I. M50I was identified in our subtype C IN sequence and this polymorphism has been reported to reduce DTG susceptibility when found in combination with the mutation R263K in HIV-1 subtype B IN [43, 44] However, in our study the mutation R263K was not present. Furthermore, M50I is not able to cause drug resistance on its own, but increases the effect of resistance exhibited by R263K [43] In our study M50I had no effect on INSTI's binding to IN. A comparison of the backbone structure of the modelled IN structures to one another showed high similarity with less than 0.4Å backbone deviation found between the 3 variants calculated from RMSD analysis. Our IN homology modelling showed one slight secondary structural feature alteration within the N-terminal domain. Subtype B displayed a helical turn absent in Subtype C and CRF02_AG IN. Secondary structural features, such as helices may influence the efficacy of drugs upon proteins, either by directly changing binding pocket properties or through affecting stability of the whole protein [45] . No alteration to the binding site properties implicating the helix was noted in our study. This might be attributed to the distance away from the active site, which is within the Catalytic core domain.
Molecular docking showed that all INSTIs are able to bind to either of the tested IN subtype structures with plausible binding poses. No significantly reduced binding affinity was observed for each of the INSTIs, implying no alteration to the binding site, which may prevent INSTI drug binding. However, differences in binding affinity are present. The Binding affinity is an indication of how strong the ligand is binding to the active site. The tested INSTIs bound consistently stronger to subtype B IN than either CRF_02_AG IN or subtype C IN, albeit that the differences in binding affinity were minimal. This may be attributable to INSTI development largely having taken place in subtype B predominant populations. The implication being that we predict INSTIs to likely stay bound for a shorter amount of time to CRF_02_AG or Subtype C as compared with subtype B IN. Experimental binding affinity assays need to be conducted to support this finding. EVG susceptibility reducing NOPs associated with reduction to susceptibility to EVG have been previously reported to occur with a relatively high frequency within CRF02_AG IN, however those NOPs were not identified in our study [46 -48] .
Magnesium ions are responsible for the binding of DNA, INSTIs competitively inhibit this process by binding to the magnesium ions. It was therefore expected that interaction analysis would reveal that an interaction(s) takes place between the docked INSTIs and magnesium ions present within integrase active sites. The interaction(s) with magnesium ions are considered to be essential for inhibition to take place whereas other interactions are considered non-essential for the activity of INSTIs to take place. Therefore, in this study we considered an INSTI to be successfully bound if interaction analysis predicted interactions occurring with magnesium ions, it may however be likely that NOPs favour or reduce the likelihood of additional interactions occurring enhancing binding affinity. It should be emphasised that our molecular docking assays were not performed on IN-DNA complexes, it has been widely reported that INSTI binding is strengthened in the presence of viral DNA. Omission of viral DNA from our reported integrase structures allowed for the direct assessment of the impact the NOPs have on INSTI drug binding [49] .
Binding site analysis further support the results from the molecular docking. The analyses conducted show that binding sites between each IN structures are identical. One NOP I151V is present within the binding sites of our study but does not induce any effect beyond a slight spatial change due to its different side chain orientation. Future work will include molecular dynamic simulation studies of the different protein-MG-drug complexes to estimate free energy of ligand binding to different IN conformations to include polar solvation and entropy effects.
Conclusion
Our study show that unique polymorphisms within geographically distinct HIV-1 infected populations with different variants do not prevent INSTI binding. However, polymorphisms may affect the strength of the binding of INSTI's and possibly favour drug resistance mutations. We therefore put forward that second generation DTG should be added to anti-viral regimens as part of first-line regimens, this would account for cross-resistance which may occur between EVG and RAL as DTG has a higher genetic barrier to resistance. 
